0QNO Stock Chart & Stats
CHF570.79
CHF5.11(0.90%)
At close: 4:00 PM EDT
CHF570.79
CHF5.11(0.90%)
Day’s Range― - ―
52-Week RangeCHF455.10 - CHF591.00
Previous CloseN/A
Volume212.00
Average Volume (3M)60.23K
Market Cap
CHF38.34B
Enterprise ValueCHF41.89K
Total Cash (Recent Filing)CHF487.00M
Total Debt (Recent Filing)CHF4.17B
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Jan 27, 2027EPS Estimate
9.3Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)-1.54
Shares Outstanding70,229,020
10 Day Avg. Volume72,998
30 Day Avg. Volume60,227
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)4.13
Price to Sales (P/S)5.78
P/FCF Ratio-185.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF698.29Price Target Upside22.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)18.1
Revenue Forecast (FY)CHF7.12B
Bulls Say, Bears Say
Bulls Say
Business ExpansionLeading biologics contract drug service provider expanding even more.
Contract SigningsLonza disclosed CHF10bn of contract signing during 2024, indicating strong business development and future revenue potential.
Revenue PotentialLonza will continue expanding its ADC services through R&D and acquisitions, which would boost its revenue potential and share price as the market sees increased ADC exposure to be a share price driver.
Bears Say
Capsules SegmentCapsules & Health Ingredients segment experienced a 13% EBITDA miss due to destocking in pharma capsules and negative pricing in nutraceuticals.
Divisional GuidanceThe company is also not going to disclose divisional guidance going forward, which may disappoint some.
Market CompetitionLonza is at risk of losing market share to players that have better growth potential.
Lonza Group Ltd News
0QNO FAQ
What was Lonza Group Ltd’s price range in the past 12 months?
Lonza Group Ltd lowest share price was CHF455.10 and its highest was CHF591.00 in the past 12 months.
What is Lonza Group Ltd’s market cap?
Lonza Group Ltd’s market cap is CHF38.34B.
When is Lonza Group Ltd’s upcoming earnings report date?
Lonza Group Ltd’s upcoming earnings report date is Jan 27, 2027 which is in 164 days.
How were Lonza Group Ltd’s earnings last quarter?
Lonza Group Ltd released its earnings results on Jul 22, 2026. The company reported CHF8.16 earnings per share for the quarter, missing the consensus estimate of CHF8.631 by -CHF0.471.
Is Lonza Group Ltd overvalued?
According to Wall Street analysts Lonza Group Ltd’s price is currently Undervalued.
Does Lonza Group Ltd pay dividends?
Lonza Group Ltd pays a Annually dividend of CHF5 which represents an annual dividend yield of 0.89%. See more information on Lonza Group Ltd dividends here
What is Lonza Group Ltd’s EPS estimate?
Lonza Group Ltd’s EPS estimate is 9.3.
How many shares outstanding does Lonza Group Ltd have?
Lonza Group Ltd has 70,229,020 shares outstanding.
What happened to Lonza Group Ltd’s price movement after its last earnings report?
Lonza Group Ltd reported an EPS of CHF8.16 in its last earnings report, missing expectations of CHF8.631. Following the earnings report the stock price went down -4.599%.
Which hedge fund is a major shareholder of Lonza Group Ltd?
Currently, no hedge funds are holding shares in GB:0QNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lonza Group Ltd
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
0QNO Stock 12 Month Forecast
Average Price Target
CHF698.29
▲(22.34% Upside)